Sysmex Inostics
Cathryn Mullen has a history of working in Quality Assurance and Management Systems in various laboratories and manufacturing companies, specializing in maintaining and improving Quality Systems in compliance with regulations. With a background in Textile Chemistry, Cathryn has also worked as a Chemist in the past. Their experience includes creating databases to track various aspects of quality management and facilitating collaboration between Manufacturing and Quality Assurance teams.
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.